The newly-added solutions provide researchers and manufacturers with high-performance, scalable, and regulatory-ready solutions that streamline cell and gene therapy workflows from discovery through clinical development
A single reader minimizes space requirements, training burden, and maintenance contracts for endotoxin detection
Lonza now offers human cord blood CD34+ hematopoietic stem cells in large batch sizes, leading the way in addressing a critical unmet market need
The agreement will provide prevalidated hepatocytes for use on innovative organ-on-a-chip range
The addition of the PyroWave XM Fluorescent Reader complements the existing absorbance readers used in traditional LAL-based assays
The new lots further enhance Lonza’s renowned human primary cell offerings as it looks to meet growing market demand for deeper cell characterization
Lonza has collaborated with CELLINK to offer a comprehensive 3-dimensional (3D) bioprinting solution designed to advance complete 3D cell culture workflows
The new medium promises to boost and optimize the production of AAV in Sf9 insect cells
The eCHO™ Medium is ideal for the manufacture of recombinant proteins for medical use, including monoclonal antibodies and complex glycoproteins
Lonza and AllCells team up to offer an extensive range of hematopoietic primary cells to reach the global scientific community
First glimpse of next-generation solution for endotoxin detection at PDA 2018
Fermentation strategy results in drastically-reduced fermentation times and high product titers up to 6 g/L
